Biostock interview Chordate Medical CEO Anders Weilandt about the new partner agreement with Neurolite AG, and why Switzerland is a new focus market for Chordate.
“The main reason was that Neurolite is entirely focused on neurology and has built up both knowledge in the field and an excellent network in the market over many years. Additionally, Neurolite is our regulatory representative, which we need since Switzerland is not part of the EU.”
Why is Switzerland an attractive market?
“Partly because headache/migraine care is well-developed, similar to Germany, and partly because the distribution between private and public healthcare is advantageous for us. The decision-making processes are decentralized and relatively quick compared to many other markets. Since we are building proof-of-concept, deep market penetration is more important than broad market penetration. Initially, we want to attract a smaller number of highly engaged clinics, rather than many with lower engagement.”
